Genomic investigation and clinical correlates of the in vitro β-lactam: NaHCO3 responsiveness phenotype among methicillin-resistant Staphylococcus aureus isolates from a randomized clinical trial
Neta Petersiel,Stefano Giulieri,Diane S. Daniel,Sook-Ha Fan,Selvi C. Ersoy,Joshua S. Davis,Arnold S. Bayer,Benjamin P. Howden,Steven Y. C. Tong,David C. Lye,Dafna Yahav,Archana Sud,J. Owen Robinson,Jane Nelson,Sophia Archuleta,Matthew A. Roberts,Alan Cass,David L. Paterson,Hong Foo,Mical Paul,Stephen D. Guy,Adrian R. Tramontana,Genevieve B. Walls,Stephen McBride,Narin Bak,Niladri Ghosh,Benjamin A. Rogers,Anna P. Ralph,Jane Davies,Patricia E. Ferguson,Ravindra Dotel,Genevieve L. McKew,Timothy J. Gray,Natasha E. Holmes,Simon Smith,Morgyn S. Warner,Shirin Kalimuddin,Barnaby E. Young,Naomi Runnegar,David N. Andresen,Nicholas A. Anagnostou,Sandra A. Johnson,Mark D. Chatfield,Allen C. Cheng,Vance G. Fowler,Benjamin P. Howden,Niamh Meagher,David J. Price,Sebastiaan J. van Hal,Matthew V. N. O'Sullivan,on behalf of the CAMERA2 study group
DOI: https://doi.org/10.1128/aac.00218-24
IF: 5.938
2024-06-06
Antimicrobial Agents and Chemotherapy
Abstract:ABSTRACT NaHCO 3 responsiveness is a novel phenotype where some methicillin-resistant Staphylococcus aureus (MRSA) isolates exhibit significantly lower minimal inhibitory concentrations (MIC) to oxacillin and/or cefazolin in the presence of NaHCO 3 . NaHCO 3 responsiveness correlated with treatment response to β-lactams in an endocarditis animal model. We investigated whether treatment of NaHCO 3 -responsive strains with β-lactams was associated with faster clearance of bacteremia. The CAMERA2 trial (Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus ) randomly assigned participants with MRSA bloodstream infections to standard therapy, or to standard therapy plus an anti-staphylococcal β-lactam (combination therapy). For 117 CAMERA2 MRSA isolates, we determined by broth microdilution the MIC of cefazolin and oxacillin, with and without 44 mM of NaHCO 3 . Isolates exhibiting ≥4-fold decrease in the MIC to cefazolin or oxacillin in the presence of NaHCO 3 were considered “NaHCO 3 -responsive” to that agent. We compared the rate of persistent bacteremia among participants who had infections caused by NaHCO 3 -responsive and non-responsive strains, and that were assigned to combination treatment with a β-lactam. Thirty-one percent (36/117) and 25% (21/85) of MRSA isolates were NaHCO 3 -responsive to cefazolin and oxacillin, respectively. The NaHCO 3 -responsive phenotype was significantly associated with sequence type 93, SCC mec type IVa, and mecA alleles with substitutions in positions −7 and −38 in the regulatory region. Among participants treated with a β-lactam, there was no association between the NaHCO 3 -responsive phenotype and persistent bacteremia (cefazolin, P = 0.82; oxacillin, P = 0.81). In patients from a randomized clinical trial with MRSA bloodstream infection, isolates with an in vitro β-lactam-NaHCO 3 -responsive phenotype were associated with distinctive genetic signatures, but not with a shorter duration of bacteremia among those treated with a β-lactam.
pharmacology & pharmacy,microbiology